The use and reporting of the cross-over study design in clinical trials and systematic reviews: A systematic assessment

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Nolan, Sarah Jane ^a,b   Hambleton, Ian ^b,c   Dwan, Kerry ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Cochrane Cystic Fibrosis and Genetic Disorders Group ^*  (United Kingdom)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

^d Cochrane Editorial Unit ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL STUDY; CYSTIC FIBROSIS; GENETIC DISORDER; PARALLEL DESIGN; QUALITY CONTROL; REVIEW; SAMPLE SIZE; STUDY DESIGN; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); CROSSOVER PROCEDURE; GENETICS; HUMAN; META ANALYSIS; PROCEDURES;

CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; CYSTIC FIBROSIS; HUMANS;

EID: 84978715207     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159014     Document Type: Review

References (18)

1. Senn SJ. Cross-over trials in clinical research. Chichester: John Wiley. 2002
2. Brown BW Jr. The crossover experiment for clinical trials. Biometrics. 1980; 36: 69-79. PMID: 7370374
3. Louis TA, Lavori PW, Bailar JC, Polansky M. Crossover and self-controlled designs in clinical research. NEJM 1984, 310:24-31. PMID: 6689736
4. Mills EJ, Chan AW, Wu P, Vail A, Guyatt GH, Altman DG. Design, analysis, and presentation of crossover trials. Trials. 2009; 30(10): 27.
5. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epid. 2002; 31:140-149.
6. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochranehandbook.org.
7. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Stat Med. 2002; 21: 2131-2144 PMID: 12210629
8. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Stat Med. 2002; 21: 2145-2159. PMID: 12210630
9. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Stat Med. 2002; 21: 2161-2173. PMID: 12210631
10. Altman D. Better reporting of randomised controlled trials: the CONSORT statement. BMJ. 1996; 313, 570-571 PMID: 8806240
11. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340:c332. doi: 10.1136/bmj.c332PMID: 20332509
12. Becker MP, Balagtas CC. Marginal modeling of binary cross-over data. Biometrics 1993; 49(4): 997-1009. PMID: 8117910
13. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979; 8 (1): 7-20PMID: 552299
14. Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Amer Statist Assoc 1937; 32(200): 675-701.
15. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics. 1965; 21(2) 467-480.
16. Lehmacher W. Analysis of the crossover design in the presence of residual effects. Stat Med 1991; 10 (6): 891-899. PMID: 1876779
17. Lathyris DN, Trikalinos TA, Ioannidis JPA. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. Int J Epidemiol. 2007; 36(2): 422-430. PMID: 17301102
18. Higgins JPT, Deeks JJ, Altman DG, editors. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.